Axogen Upsizes Stock Offering to $124 Million to Clear Debt and Fund Growth

Tampa, Thursday, 22 January 2026.
Axogen, Inc. has significantly expanded its capital raising targets, pricing an upsized public offering at $124 million—far exceeding the initially proposed $85 million. The biotechnology leader in peripheral nerve repair priced 4 million shares at $31.00 each, aiming to utilize the proceeds for the early repayment of its Oberland Capital debt and to fund general corporate growth. While this substantial capital injection streamlines the company’s balance sheet, the immediate market response saw shares slip in after-hours trading. This financing follows the company’s recent FDA approval for its Avance nerve graft, signaling a strategic pivot toward aggressive operational scaling despite short-term stock volatility.